Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Nephrology Dialysis Transplantation · 01.04.2025 · 40 (4) · 720-730
DOI: 10.1093/ndt/gfae203 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 14.09.2024. Verfasst von Kaitlin J Mayne und 18 weiteren Autor:innen. Beteiligte Einrichtung: Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Ox…. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Uric Acid, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Clinical Trial Service Unit and Epidemiological Studies Unit.
Abstract (Originalsprache)
Background
Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium–glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.
Methods
The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen–Gill extension (total events). A post hoc composite outcome included new initiation of uric acid–lowering therapy or colchicine. EMPA-KIDNEY primary and kidney disease progression outcomes were also assessed in subgroups of baseline serum uric acid.
Results
Baseline mean ± standard deviation serum uric acid concentration was 431 ± 114 µmol/l. Allocation to empagliflozin resulted in a study-average between-group difference in serum uric acid of −25.6 µmol/l [95% confidence interval (CI) −30.3 to −21.0], with larger effects in those with higher eGFR (trend P < .001) and without diabetes (heterogeneity P < .001). Compared with placebo, empagliflozin did not significantly reduce first or total gout events [hazard ratio 0.87 (95% CI 0.74–1.02) for the 595 first events and 0.86 (0.72–1.03) for the 869 total events] with similar hazard ratios for the post hoc composite and across subgroups, including by diabetes and eGFR. The effect of empagliflozin on the primary outcome and kidney disease progression outcomes were similar irrespective of the baseline level of uric acid.
Conclusions
SGLT2 inhibition reduces serum uric acid in patients with CKD, with larger effects at higher eGFR and in the absence of diabetes. However, the effect on uric acid is modest and did not translate into reduced risk of gout in EMPA-KIDNEY.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- University of Toronto, Toronto, ON, Canada.
- Duke Clinical Research Institute, Durham, NC, USA.
- University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Kaitlin J Mayne, Emily Sammons, Jonathan Emberson, Martin J Landray, Colin Baigent, Christoph Wanner, Richard Haynes, William G Herrington
Förderung
- Medical Research Council
- Clinical Trial Service Unit and Epidemiological Studies Unit
Zitieren
APA
Mayne, K. J., Sardell, R. J., Staplin, N., Judge, P. K., Zhu, D., Sammons, E., Cherney, D. Z. I., Green, J. B., Levin, A., Pontremoli, R., Hauske, S. J., Emberson, J., Preiss, D., Landray, M. J., Baigent, C., Wanner, C., Haynes, R., Herrington, W. G., & EMPA-KIDNEY Collaborative Group (2025). Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 40(4), 720-730. https://doi.org/10.1093/ndt/gfae203
Vancouver
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, et al. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation. 2025;40(4):720-730. doi:10.1093/ndt/gfae203
BibTeX
@article{Mayne2025,
author = {Mayne, Kaitlin J and Sardell, Rebecca J and Staplin, Natalie and Judge, Parminder K and Zhu, Doreen and Sammons, Emily and Cherney, David Z I and Green, Jennifer B and Levin, Adeera and Pontremoli, Roberto and Hauske, Sibylle J and Emberson, Jonathan and Preiss, David and Landray, Martin J and Baigent, Colin and Wanner, Christoph and Haynes, Richard and Herrington, William G and EMPA-KIDNEY Collaborative Group, EMPA-KIDNEY Collaborative Group},
title = {Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {4},
pages = {720--730},
doi = {10.1093/ndt/gfae203}
}
EUVIMED